University of Virginia Patent Foundation

Tearsolutions, Inc.

Wang, Jiahu

Gordon W Laurie

Rajesh Kumar

Thomas R Gadek

Sandhya Sanghi

Kumar Rajesh

Angela J Lumsden

Kenneth Brayman

Paul A Laskar

Preeti Chhabra

Karina Teixeira

Mingyang Ma

Marc G Odrich

Michelle Carpenter

Rebecca A Ogle

J Douglas Glass

Michelle L Matter

Lanlin Chen

Jiahu Wang

Peisong Ma

Compositions and methods for regenerating pancreatic islet viability and/or cell proliferation in vitro, ex vivo, and/or in vivo; and/or for regenerating glucose-stimulated insulin secretion; and/or for regenerating viability and/or cell proliferation of a transplanted pancreatic islets; and/or for preventing and/or inhibiting rejection of a transplanted islets; and/or for pancreatic islet transplantation; and/or for treating a symptom of a condition, disorder, or disease associated with abnormal insulin responsiveness to glucose are provided. In some embodiments, the compositions include a peptide and/or a pharmaceutically acceptable salt thereof, and/or a biologically active fragment, analog, or derivative thereof, wherein the peptide, the pharmaceutically acceptable salt thereof, and/or the biologically active fragment, analog, or derivative thereof has an amino acid sequence of any of SEQ ID NOs: 1-60, or any combination thereof.

Compositions and methods for promoting islet viability and enhancing insulin secretion

This application generally relates to stable peptide compositions and kits comprising low levels of buffering and chelating agents, and methods of using the same.

Stable peptide compositions

The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a &#x2dc;90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a &#x2dc;25 kDa syndecan-1 fragment is detectable in dry, but not normal tears.

Compositions and methods for treating eye infections and disease

The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a &#x2dc;90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a &#x2dc;25 kDa syndecan-1 fragment is detectable in dry, but no normal tears.

The present invention relates to methods and compositions useful for the regulation of lacritin, syndecan, and lacritin-syndecan interactions and the signaling pathway downstream of lacritin-syndecan interactions. The invention also relates to regulating lacritin-syndecan interaction to regulate ocular cell survival in response to an insult or injury, in protecting against ocular inflammation, and in promoting ocular wound repair.

Lacritin-syndecan fusion proteins

The present invention relates to the use of lacritin, and fragments, derivatives, and homologs thereof, and nucleic acid sequences encoding that protein. The invention relates to the use of lacritin as a growth factor human corneal epithelial cells and other select epithelial cells. The invention also relates to the use of lacritin in promoting ocular cell survival in response to an insult or injury, in protecting against ocular inflammation, and in promoting ocular wound repair.

Use of lacritin in promoting ocular cell survival

The present invention relates to a novel lacrimal gland protein (designated lacritin) and the nucleic acid sequences encoding that protein. Lacritin has activity as a growth factor on both human corneal epithelial cells and on the lacrimal acinar cells that produce it. Accordingly, one embodiment of the present invention is directed to the use of lacritin to treat Dry Eye and other disorders requiring the wetting of the eye.

Ocular tear growth factor-like protein

The present invention relates to a novel polypeptide which has secretion enhancing activity on lacrimal and parotid gland cells, monoclonal antibodies thereto, and methods of diagnosising Sjorgren's syndrome using these antibodies.

Diagnostic for Sjogren's syndrome

The present invention provides novel cell adhesion peptides.

Growing community of inventors

Charlottesville, VA, United States of America

Gordon W Laurie